Peptide Initiative

Dosing protocol · Healing & Recovery

Thymulin Analog (PAT) dosing & administration

Synthetic thymulin-derived nonapeptide with potent analgesic and anti-inflammatory properties

Suggested dose

1 mcg–50 mcg mcg

Once dailyFrequency
Intraperitoneal injectionRoute
Ongoing/indefiniteCycle length

Dosing

How much Thymulin Analog (PAT) do I take?

Timing

Best time to take

Administer Thymulin Analog (PAT) at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.

With food?

Thymulin Analog (PAT) injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.

If stacking

Thymulin Analog (PAT) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

Adjusting your dose

Increase if

  • You've tolerated the current dose for the recommended period without significant side effects
  • Therapeutic goals haven't been met at the current dose level
  • Your healthcare provider recommends dose escalation based on your response
  • Lab work or clinical assessments support a higher dose

Decrease if

  • Side effects are bothersome or impacting daily life despite management strategies
  • You experience any signs of an adverse reaction
  • Lab results indicate the need for dose reduction
  • Your healthcare provider recommends a lower dose based on your response

Signs of right dose

  • Therapeutic goals being met with minimal side effects
  • Stable and consistent response to treatment
  • Lab values or clinical markers trending in the right direction
  • Good tolerance with manageable or absent side effects

Administration

How do I use Thymulin Analog (PAT)?

Reconstitution

What you need

  • Thymulin Analog (PAT) vial (lyophilized powder or solution)
  • Bacteriostatic water or sterile sodium chloride for reconstitution
  • Alcohol swabs for cleaning vial tops and injection sites
  • Appropriately sized syringes with fine-gauge needles (27-30 gauge)
  • Sharps disposal container

Injection

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

Storage

Before reconstitution

Store Thymulin Analog (PAT) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.

After reconstitution

Once reconstituted, Thymulin Analog (PAT) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.

Signs of degradation — discard the vial

  • Solution appears cloudy, discolored, or contains visible particles (should be clear)
  • Product has been exposed to temperatures outside the recommended storage range
  • Product has been frozen (unless specifically designed for freeze-thaw stability)
  • Expiration date has passed or reconstituted solution has exceeded its use-by date
  • Unusual odor, color change, or visible contamination

Sample daily schedule

  • As prescribed (once daily)

    As prescribed by your healthcare provider injection

    Site: Intraperitoneal injection—rotate sites if applicable

    Maintain a consistent schedule for optimal results with Thymulin Analog (PAT). Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.

Safety

Is Thymulin Analog (PAT) safe?

Side effects

Commonly reported: Injection Site Reaction, Transient Immune Modulation, Mild Sedation, Short Duration of Action

Less common: Potential Immune Suppression, CNS Effects with Central Administration

Serious side effects

  • Unintended Immune Stimulation

Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Thymulin Analog (PAT)
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Thymulin Analog (PAT) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

Flagged pairings

  • Strong Immunosuppressants — May compound immune suppression through overlapping anti-inflammatory mechanisms
  • Nicotinic Receptor Antagonists — Alpha-7 nAChR antagonists like methyllycaconitine block PAT primary mechanism of action
  • High-Dose Corticosteroids — Redundant anti-inflammatory pathways may confound research outcomes or cause excessive immune suppression

Published research

What the studies show

  • Strong human trials (Phase 3 or FDA approved)
  • Research compound
  1. Targeting inflammatory components in neuropathic pain: The analgesic effect of thymulin related peptide

    Safieh-Garabedian B, et al. · 2019PubMed

    Thymulin-related peptides target inflammatory components in neuropathic pain by reducing cytokine-mediated neuroinflammation. These peptides regulate inflammatory mediators for novel therapeutic approaches to chronic pain.

  2. Involvement of alpha-7 nicotinic acetylcholine receptors in the anti-inflammatory action of PAT

    Safieh-Garabedian B, et al. · 2013PubMed

    PAT demonstrated anti-inflammatory action through potentiation of alpha-7 nicotinic acetylcholine receptors, reversing inflammatory nociceptive hyperactivity in rats. The mechanism differed from traditional analgesics.

  3. Role of thymulin or its analogue as a new analgesic molecule

    Dardenne M, et al. · 2006PubMed

    No abstract available for comprehensive analysis.

  4. A thymulin analogue peptide with powerful inhibitory effects on pain of neurogenic origin

    Saadé NE, et al. · 2003PubMed

    Thymulin analog PAT produced powerful neuropathic pain reduction equal to morphine in chronic constriction and spared nerve injury models. Daily treatment progressively attenuated all neuropathic manifestations.

  5. Potent analgesic and anti-inflammatory actions of a novel thymulin-related peptide in the rat

    Safieh-Garabedian B, et al. · 2002PubMed

    PAT significantly reduced inflammatory hyperalgesia in rats through dose-dependent decrease in pro-inflammatory cytokines. Analgesic effects matched dexamethasone and indomethacin.

Head to head

Thymulin Analog (PAT) compared

Want the full picture?

The complete Thymulin Analog (PAT) research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.